title: FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia.
abstract: A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matched-sibling donor. The patient's pre- and post transplant course were complicated by an autoimmune disorder and her post transplant course was complicated by severe hepatic and gastrointestinal GVHD. A technetium-99m sulfur colloid scan 4 months post transplant and bone marrow studies 8 months post transplant demonstrated intramedullary hematopoiesis, complete resolution of marrow fibrosis, and partial resolution of osteosclerosis.
authors.affiliation: University of California, San Diego School of Medicine, La Jolla, CA, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Tanner
authors.forename: C K
authors.initials: CK
authors.lastname: Hoh
authors.forename: A
authors.initials: A
authors.lastname: Bashey
authors.forename: P
authors.initials: P
authors.lastname: Holman
authors.forename: C
authors.initials: C
authors.lastname: Sun
authors.forename: H E
authors.initials: HE
authors.lastname: Broome
authors.forename: T
authors.initials: T
authors.lastname: Lane
authors.forename: E D
authors.initials: ED
authors.lastname: Ball
authors.forename: E
authors.initials: E
authors.lastname: Carrier
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006086:Graft vs Host Disease / Q000473:pathology; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010026:Osteosclerosis / Q000000981:diagnostic imaging; D055728:Primary Myelofibrosis / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy*; D011877:Radionuclide Imaging; D012074:Remission Induction; D013163:Splenomegaly; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D007166:Immunosuppressive Agents; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D014740:Vidarabine